NanoString Highlights Advances in Product Pipeline and Application Development at the 2018 Association of Molecular Pathology Conference

Demonstrates Potential of Hyb & Seq NGS Platform for Infectious Disease Applications

SEATTLE, Oct. 30, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today highlighted advances in product development that will be presented at the Association of Molecular Pathology conference in San Antonio, Texas, October 31st - November 3rd.   

“We’re excited to have the opportunity to showcase the capabilities of our three molecular profiling platforms – nCounter®, GeoMx™ DSP, and Hyb & Seq™ NGS,” said Brad Gray, president and CEO of NanoString. “In particular, multiple presentations highlight how the simple workflow and rapid turnaround time of Hyb & Seq technology could open up new clinical applications for Next-Generation Sequencing in the field of infectious disease, where the ability to rapidly and accurately identify pathogens across biological kingdoms and perform Antibiotic Susceptibility Testing (AST) would address major unmet needs.”

Introducing Hyb & Seq™ NGS Platform for Infectious Disease Applications
Corporate Workshop: Rapid Pathogen Identification and Phenotypic Antibiotic Susceptibility Testing (AST) Using Hyb & Seq™ Technology
Roby P. Bhattacharyya, MD, Ph.D., Assistant in Medicine, Division of Infectious Diseases, Massachusetts
General Hospital and Joseph M. Beechem, Ph.D., Senior Vice President of Research and Development, NanoString Technologies
Wednesday, October 31, 9:00 – 9:50 AM CT, Room 304AB

Scientific Session: A Quantitative, Multiplexed RNA Detection Platform for Rapid Pathogen Identification and Phenotypic Antibiotic Susceptibility Testing (AST) using NanoString Technology
Roby P. Bhattacharyya, MD, Ph.D., Massachusetts General Hospital
Friday, November 2, 11:15 – 11:30 AM CT, Infectious Disease Platform Presentations

Poster: Rapid and Accurate Cross-Kingdom Human Pathogen Identification and Detection using Hyb & Seq™ Technology
Christopher E. Mason, Ph.D., Weill Cornell Medicine
Saturday, November 3, 9:45 – 10:45 AM CT, Poster #ID051

Advances in Digital Spatial Profiling with GeoMx™
Corporate Workshop: High-plex digital spatial profiling enables characterization of complex immune biology in the tumor microenvironment of mesothelioma
Bernard A. Fox, Ph.D., Harder Family Chair for Cancer Research, Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center Portland, Oregon
Wednesday, October 31, 11:00 – 11:50 AM CT, Room 304AB

Poster: Characterization of the Tumor Microenvironment using a Novel High-plex Protein Imaging Technology
Douglas Hinerfeld, Poster Number: ST060, Abstract Number: 16195, Category: Solid Tumors
Friday, November 2, 2:30 – 3:30 PM CT

Poster: Validation of antibody panels for high-plex immunohistochemistry applications
Douglas Hinerfeld, Poster Number: ST057, Abstract Number: 16190, Category: Solid Tumors
Saturday, November 3, 9:45 – 10:45 AM CT

nCounter® Analysis System
Corporate Workshop: Tackling the Challenge of Translational Gene Signature Development
Harvey Pass, MD Chief, Thoracic Oncology NYU Cancer Center and Jean Wang, MD, PhD, FRCPC, Clinician Scientist and Staff Hematologist, DMOH, UHN Affiliate Scientist, Princess Margaret Cancer Centre, Toronto
Wednesday October 31, 10:00 – 10:50 AM CT, Room: 304AB

You can visit NanoString Technologies at booth #888 at the Henry B. Gonzalez Convention Center in San Antonio, Texas, November 1-3, 2018.

About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 2,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

For more information, please visit

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the potential of the company’s Hyb and Seq NGS Platform for future clinical applications such as infectious disease. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include product development or clinical studies; market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; delays or denials of reimbursement for diagnostic products; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.

The NanoString logo, NanoString, NanoString Technologies, GeoMx, Hyb and Seq, nCounter and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.


Doug Farrell
Vice President, Investor Relations & Corporate Communications
Phone: 206-602-1768